Cargando…

The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life

A drug’s biological half-life is defined as the time required for the human body to metabolize or eliminate 50% of the initial drug dosage. Correctly measuring the half-life of a given drug is helpful for the safe and accurate usage of the drug. In this study, we investigated which gene ontology (GO...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu-Hang, Chu, Chen, Wang, Shaopeng, Chen, Lei, Lu, Jing, Kong, XiangYin, Huang, Tao, Li, HaiPeng, Cai, Yu-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079577/
https://www.ncbi.nlm.nih.gov/pubmed/27780226
http://dx.doi.org/10.1371/journal.pone.0165496
_version_ 1782462568118353920
author Zhang, Yu-Hang
Chu, Chen
Wang, Shaopeng
Chen, Lei
Lu, Jing
Kong, XiangYin
Huang, Tao
Li, HaiPeng
Cai, Yu-Dong
author_facet Zhang, Yu-Hang
Chu, Chen
Wang, Shaopeng
Chen, Lei
Lu, Jing
Kong, XiangYin
Huang, Tao
Li, HaiPeng
Cai, Yu-Dong
author_sort Zhang, Yu-Hang
collection PubMed
description A drug’s biological half-life is defined as the time required for the human body to metabolize or eliminate 50% of the initial drug dosage. Correctly measuring the half-life of a given drug is helpful for the safe and accurate usage of the drug. In this study, we investigated which gene ontology (GO) terms and biological pathways were highly related to the determination of drug half-life. The investigated drugs, with known half-lives, were analyzed based on their enrichment scores for associated GO terms and KEGG pathways. These scores indicate which GO terms or KEGG pathways the drug targets. The feature selection method, minimum redundancy maximum relevance, was used to analyze these GO terms and KEGG pathways and to identify important GO terms and pathways, such as sodium-independent organic anion transmembrane transporter activity (GO:0015347), monoamine transmembrane transporter activity (GO:0008504), negative regulation of synaptic transmission (GO:0050805), neuroactive ligand-receptor interaction (hsa04080), serotonergic synapse (hsa04726), and linoleic acid metabolism (hsa00591), among others. This analysis confirmed our results and may show evidence for a new method in studying drug half-lives and building effective computational methods for the prediction of drug half-lives.
format Online
Article
Text
id pubmed-5079577
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50795772016-11-04 The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life Zhang, Yu-Hang Chu, Chen Wang, Shaopeng Chen, Lei Lu, Jing Kong, XiangYin Huang, Tao Li, HaiPeng Cai, Yu-Dong PLoS One Research Article A drug’s biological half-life is defined as the time required for the human body to metabolize or eliminate 50% of the initial drug dosage. Correctly measuring the half-life of a given drug is helpful for the safe and accurate usage of the drug. In this study, we investigated which gene ontology (GO) terms and biological pathways were highly related to the determination of drug half-life. The investigated drugs, with known half-lives, were analyzed based on their enrichment scores for associated GO terms and KEGG pathways. These scores indicate which GO terms or KEGG pathways the drug targets. The feature selection method, minimum redundancy maximum relevance, was used to analyze these GO terms and KEGG pathways and to identify important GO terms and pathways, such as sodium-independent organic anion transmembrane transporter activity (GO:0015347), monoamine transmembrane transporter activity (GO:0008504), negative regulation of synaptic transmission (GO:0050805), neuroactive ligand-receptor interaction (hsa04080), serotonergic synapse (hsa04726), and linoleic acid metabolism (hsa00591), among others. This analysis confirmed our results and may show evidence for a new method in studying drug half-lives and building effective computational methods for the prediction of drug half-lives. Public Library of Science 2016-10-25 /pmc/articles/PMC5079577/ /pubmed/27780226 http://dx.doi.org/10.1371/journal.pone.0165496 Text en © 2016 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zhang, Yu-Hang
Chu, Chen
Wang, Shaopeng
Chen, Lei
Lu, Jing
Kong, XiangYin
Huang, Tao
Li, HaiPeng
Cai, Yu-Dong
The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life
title The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life
title_full The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life
title_fullStr The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life
title_full_unstemmed The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life
title_short The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life
title_sort use of gene ontology term and kegg pathway enrichment for analysis of drug half-life
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079577/
https://www.ncbi.nlm.nih.gov/pubmed/27780226
http://dx.doi.org/10.1371/journal.pone.0165496
work_keys_str_mv AT zhangyuhang theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT chuchen theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT wangshaopeng theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT chenlei theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT lujing theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT kongxiangyin theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT huangtao theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT lihaipeng theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT caiyudong theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT zhangyuhang useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT chuchen useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT wangshaopeng useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT chenlei useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT lujing useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT kongxiangyin useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT huangtao useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT lihaipeng useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife
AT caiyudong useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife